HIGHLIGHTS
SUMMARY
Change in patient shares in the "world with infliximab SC" scenario is based on clinical assumption, given that retaining infliximab (arguably the most effective firstline biologic therapy in IBD) will impact the utilization of subsequent lines of biologic therapies. Given the limited treatment options in IBD, a further SC treatment option will increase the duration of anti-TNF treatment because patients will cycle through the anti-TNF class before moving on to a further line of biologics. The model assumes less than absolute 1% change in market share changes in both vedolizumab and ustekinumab . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.